Nurse Practitioner in Cripple Creek, CO Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Mrs. Alessandra Marie Bullis, FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 412 N C St, Cripple Creek, CO 80813 Phone: 719-776-4310 Fax: 719-776-4320 |
Lisa Marie Thompson, NP Nurse Practitioner - Acute Care Medicare: Medicare Enrolled Practice Location: 412 N C St, Cripple Creek, CO 80813 Phone: 719-820-7740 |
Ambyr Dawn Hodkins, FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 412 N C St, Cripple Creek, CO 80813 Phone: 719-820-7740 Fax: 719-358-8299 |
News Archive
Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke
An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.
UA study helps better understand LGBT ally behaviors among college athletes
The sports world has not always been considered the most inviting place for those who identify as gay, lesbian, bisexual or transgender.
FUJIFILM to interface Raytheon BBN Technologies' SDM technology with its Aspire HD FFDM system
Raytheon BBN Technologies, a wholly-owned subsidiary of Raytheon Company, has licensed its patented, award-winning stereo digital mammography (SDM) technology to FUJIFILM Corp.
Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol
Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.
Implicit wins $16.3 million U.S. government contract to develop its clinical stage drug oglufanide disodium
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
› Verified 6 days ago